Clinical Trial Update: Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study of nalbuphine ER in hemodialysis patients with uremic pruritus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus
• Uremic Pruritus

Drugs mentioned

• Nalbuphine HCl ER (nalbuphine hydrochloride extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Uremic Pruritus, Pruritus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-09-07